StockData
Puma Biotechnology, Inc. logo

Puma Biotechnology, Inc. (PBYI) stock

PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 14/3011% below fair value
$7.77−0.31 (-3.84%)

Close on Nov 13, 2026Market cap $401.09MP/E 16.9Yield –

Puma Biotechnology, Inc. grew revenue 9.4% to $231.83M over the twelve months to Sep 30, 2026. Operating income fell 22.1% to $26.14M, moving the operating margin from 15.8% to 11.3%. Free cash flow was $46.07M, up 7.5% from a year earlier. At the latest close the market valued the company at $401.09M, 16.9 times its earnings.

Revenue
$231.83M
+9.4% vs. a year earlier
Operating income
$26.14M
-22.1% vs. a year earlier
Free cash flow
$46.07M
+7.5% vs. a year earlier
EPS, diluted
$0.46
-37.8% vs. a year earlier

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026

Valuation

Market cap
$401.09M
P/E ratio
16.9
Price to sales
1.73
Price to book
2.74
Dividend yield
–
Free cash flow yield
11.49%

Fundamentals

Revenue
$231.83M
Net income
$23.83M
EPS, diluted
$0.46
Free cash flow
$46.07M
Book value per share
$2.76
Diluted shares
53M

Trading

Next earnings
Feb 25, 2027 (estimated, after the close)
Previous close
$8.08
Open
$8.08
Day's range
$7.75 – $8.12
Volume
403,673
Average volume (20 days)
469,440
Index membership
Russell 2000 (since Sep 2024)
Beta (5 years)
0.97
52-week range
$4.76 – $11.50
RSI (14 days)
28.1
Volatility (1 year)
52.4%
Relative volume
1.14×
WACC
10.0%

On 1 of our idea list: Depreciation running out

Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Market cap history

Month-end market cap since 2012, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

PeriodPBYIS&P 500DifferencePBYI per yearS&P 500 per year
1 month-23.2%-3.0%−20.2 pts
3 months-10.8%-2.8%−8.0 pts
Year to date+30.6%+11.5%+19.1 pts
1 year+57.0%+13.5%+43.5 pts
3 years+104.5%+77.7%+26.8 pts+26.9%+21.1%
5 years+108.9%+72.6%+36.3 pts+15.9%+11.5%
10 years-84.6%+308.2%−392.7 pts-17.1%+15.1%

Fifteen years at a glance

Fiscal years 2011 to 2025 and trailing twelve months, USD

Revenue

$231.83M+9.4% YoY

Gross profit

$170.60M+4.6% YoY

Operating income

$26.14M-22.1% YoY

Net income

$23.83M-35.6% YoY

EPS, diluted

$0.46-37.8% YoY

Free cash flow

$46.07M+7.5% YoY
Reported periodTrailing twelve months

Press releases

Releases Puma Biotechnology filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Puma Biotechnology

Pharmaceutical Preparations

Puma Biotechnology is a biopharmaceutical company focused on the development and commercialization of products for cancer care. Its primary commercial product is Nerlynx, an oral tablet formulation of neratinib used to treat specific forms of HER2-positive breast cancer. In addition, the company is developing alisertib, an in-licensed selective small-molecule inhibitor of Aurora Kinase A for potential use against lung and breast cancers. Puma Biotechnology serves healthcare providers and cancer patients requiring targeted oncology treatments.

Company profile, executives and history

Puma Biotechnology stock: common questions

What is Puma Biotechnology's stock price?

PBYI closed at $7.77 on Nov 13, 2026, down 3.84% on the day. Over the past 52 weeks it traded between $4.76 and $11.50.

What is Puma Biotechnology's market cap?

Puma Biotechnology was worth $401.09M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.

What is PBYI's P/E ratio?

PBYI trades at 16.9 times earnings, based on diluted earnings per share of $0.46 over the twelve months to Sep 30, 2026.

How much revenue does Puma Biotechnology make?

Puma Biotechnology reported revenue of $231.83M for the twelve months to Sep 30, 2026, up 9.4% from a year earlier.

Does Puma Biotechnology pay a dividend?

No. Puma Biotechnology has not paid a cash dividend over the last twelve months.

When does Puma Biotechnology report earnings next?

Puma Biotechnology is expected to report Q4 FY2026 results on Feb 25, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.

How has PBYI stock performed over the past year?

Including dividends, PBYI returned +57.0% over the past year, against +13.5% for the S&P 500.

How many PBYI shares are sold short?

4M shares were sold short at the latest FINRA report, 10.27% of the float, or 11.5 days of average trading volume.

Who are Puma Biotechnology's competitors?

Companies most similar to Puma Biotechnology by business, industry and size include NUVB, RIGL, IDYA, URGN, SNDX.

See a number that looks wrong?